Nothing Special   »   [go: up one dir, main page]

WO2007046868A3 - Thiazolidine derivatives and their uses as therapeutic agents - Google Patents

Thiazolidine derivatives and their uses as therapeutic agents Download PDF

Info

Publication number
WO2007046868A3
WO2007046868A3 PCT/US2006/019357 US2006019357W WO2007046868A3 WO 2007046868 A3 WO2007046868 A3 WO 2007046868A3 US 2006019357 W US2006019357 W US 2006019357W WO 2007046868 A3 WO2007046868 A3 WO 2007046868A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
thiazolidine derivatives
mammal
formula
disclosed
Prior art date
Application number
PCT/US2006/019357
Other languages
French (fr)
Other versions
WO2007046868A2 (en
Inventor
Jianmin Fu
Shifeng Liu
Original Assignee
Xenon Pharmaceuticals Inc
Jianmin Fu
Shifeng Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Jianmin Fu, Shifeng Liu filed Critical Xenon Pharmaceuticals Inc
Publication of WO2007046868A2 publication Critical patent/WO2007046868A2/en
Publication of WO2007046868A3 publication Critical patent/WO2007046868A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where p, K, J, W, V, R2, R3, R4, R4a, R5, R5a and R6 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
PCT/US2006/019357 2005-05-19 2006-05-19 Thiazolidine derivatives and their uses as therapeutic agents WO2007046868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68292705P 2005-05-19 2005-05-19
US60/682,927 2005-05-19

Publications (2)

Publication Number Publication Date
WO2007046868A2 WO2007046868A2 (en) 2007-04-26
WO2007046868A3 true WO2007046868A3 (en) 2007-07-12

Family

ID=37866350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019357 WO2007046868A2 (en) 2005-05-19 2006-05-19 Thiazolidine derivatives and their uses as therapeutic agents

Country Status (1)

Country Link
WO (1) WO2007046868A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654098A1 (en) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
KR20090040478A (en) 2006-08-24 2009-04-24 노파르티스 아게 2-(pyrazin-2-yl)-thiazole and 2-(1h-pyraz0l-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
GB0722077D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
AR072707A1 (en) 2008-07-09 2010-09-15 Sanofi Aventis HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2545864T3 (en) 2009-02-17 2015-09-16 Merck Canada Inc. New spiranic compounds useful as stearoyl-coenzyme A delta-9 desaturase inhibitors
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CN102482312A (en) 2009-08-26 2012-05-30 赛诺菲 Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US20130012709A1 (en) 2009-09-10 2013-01-10 Centre National De La Recherche Scientifique NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
KR20140084164A (en) 2011-10-15 2014-07-04 제넨테크, 인크. Scd1 antagonists for treating cancer
WO2013175474A2 (en) 2012-05-22 2013-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Selective inhibitors of undifferentiated cells
WO2016044771A1 (en) * 2014-09-18 2016-03-24 Abbvie Inc. Hat inhibitors and methods for their use
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. Compounds and uses thereof
MA47212A (en) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc TREATMENT METHODS FOR NEUROLOGICAL DISORDERS
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112021014583A2 (en) 2019-01-24 2021-10-05 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496104A1 (en) * 1978-03-22 1982-06-18 Roussel Uclaf NOVEL PRODUCTS FROM THE 3- (PIPERIDIN-4-YL) 2H-INDOL-2-ONE SERIES AND PROCESS FOR THEIR PREPARATION
JPH04182481A (en) * 1990-11-19 1992-06-30 Nisshin Flour Milling Co Ltd Rhodanine derivative
WO2001062954A2 (en) * 2000-02-24 2001-08-30 Xenon Genetics, Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496104A1 (en) * 1978-03-22 1982-06-18 Roussel Uclaf NOVEL PRODUCTS FROM THE 3- (PIPERIDIN-4-YL) 2H-INDOL-2-ONE SERIES AND PROCESS FOR THEIR PREPARATION
JPH04182481A (en) * 1990-11-19 1992-06-30 Nisshin Flour Milling Co Ltd Rhodanine derivative
WO2001062954A2 (en) * 2000-02-24 2001-08-30 Xenon Genetics, Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199232, Derwent World Patents Index; AN 1992-265155, XP002426480 *
F. C. BROWN ET AL: "Rhodanine Derivatives", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 73, 1951, pages 2357 - 2359, XP002426478 *
H. SINGH AHUJA ET AL: "Differential Effects of Rexinoids and Thiazolidinediones on Metabolic Gene Expression in Diabetic Rodents", MOLECULAR PHARMACOLOGY, vol. 59, no. 4, 2001, pages 765 - 773, XP002426477 *
J. TONELLI ET AL: "Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes", DIABETES, vol. 53, no. 6, June 2004 (2004-06-01), pages 1621 - 1629, XP002426476 *

Also Published As

Publication number Publication date
WO2007046868A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2006086447A3 (en) Pyridazine derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
MX2007000028A (en) Nicotinamide derivatives and their use as therapeutic agents.
TW200626154A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626153A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2006125181A3 (en) Piperidine derivatives and their use as stearoyl-coa desaturase modulators
WO2005011653A3 (en) Pyridazine derivatives and their use as therapeutic agents
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2005011654A3 (en) Pyridyl derivatives and their use as therapeutic agents
WO2007138472A3 (en) Triazolopyridazine derivatives
WO2007136746A3 (en) Macrocyclic compounds and their uses as stearoyl-coa desaturase
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06844101

Country of ref document: EP

Kind code of ref document: A2